CytoDyn Inc (OTCPK:CYDY)
$ 0.1351 -0.00065 (-0.48%) Market Cap: 143.01 Mil Enterprise Value: 172.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 32/100

Cytodyn Inc with Dr.Pourhassan gives an update on CytoDyn's COVID-19 path and more on Proactive Transcript

Oct 24, 2020 / NTS GMT
Steve Darling
Proactive - Moderator

Very welcome back inside our Proactive newsroom. And joining me now is Nader Pourhassan, the CEO of CytoDyn. And Nader, good to have you back. How are you?

Nader Pourhassan
CytoDyn Inc. - President & CEO

Doing great. Thank you, Steve, for having me.

Questions & Answers

Steve Darling
Proactive - Moderator

Yeah. I want to ask you a little bit about your COVID-19 trial and when do you expect this to have an approval? I know there's a process that has to go through that.

Nader Pourhassan
CytoDyn Inc. - President & CEO

So when we had DSMC, data safety monitoring committee look at the data on blinded, we did not accept the statistical penalty. So we don't see the data. And the reason we didn't do that is in the case we needed to increase the size of the trial and we had taken the statistical penalty, then we wouldn't be able to do that and that would have potentially harmed us.

So when DSMC came back and said to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot